Head-To-Head Analysis: Intellipharmaceutics International (IPCI) and Its Rivals
Intellipharmaceutics International (NASDAQ: IPCI) is one of 116 public companies in the “Pharmaceuticals” industry, but how does it contrast to its competitors? We will compare Intellipharmaceutics International to related companies based on the strength of its risk, profitability, analyst recommendations, earnings, valuation, institutional ownership and dividends.
Risk and Volatility
Intellipharmaceutics International has a beta of 1.06, indicating that its stock price is 6% more volatile than the S&P 500. Comparatively, Intellipharmaceutics International’s competitors have a beta of 0.95, indicating that their average stock price is 5% less volatile than the S&P 500.
Earnings & Valuation
This table compares Intellipharmaceutics International and its competitors gross revenue, earnings per share and valuation.
|Gross Revenue||NetIncome||Price/Earnings Ratio|
|Intellipharmaceutics International Competitors||$8,389.19||$1,123.88||9.07|
Intellipharmaceutics International’s competitors have higher revenue and earnings than Intellipharmaceutics International. Intellipharmaceutics International is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.
This table compares Intellipharmaceutics International and its competitors’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Intellipharmaceutics International Competitors||-2,859.57%||-67.91%||-9.22%|
This is a breakdown of current recommendations for Intellipharmaceutics International and its competitors, as reported by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Intellipharmaceutics International Competitors||847||3785||6815||185||2.54|
Intellipharmaceutics International presently has a consensus price target of $2.37, suggesting a potential upside of 161.54%. As a group, “Pharmaceuticals” companies have a potential upside of 10.94%. Given Intellipharmaceutics International’s higher probable upside, analysts plainly believe Intellipharmaceutics International is more favorable than its competitors.
Insider and Institutional Ownership
3.5% of Intellipharmaceutics International shares are owned by institutional investors. Comparatively, 43.7% of shares of all “Pharmaceuticals” companies are owned by institutional investors. 11.9% of shares of all “Pharmaceuticals” companies are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
Intellipharmaceutics International competitors beat Intellipharmaceutics International on 9 of the 12 factors compared.
About Intellipharmaceutics International
Intellipharmaceutics International Inc is a Canada-based pharmaceutical company engaged in the research, development and manufacture of controlled-release and targeted-release oral solid dosage drugs. Its Hypermatrix technology is a multidimensional controlled-release drug delivery platform that is applied to the development of a range of existing and new pharmaceuticals. Based on this technology platform, it has developed various drug delivery systems and a pipeline of products, and product candidates in various stages of development, in therapeutic areas that include neurology and cardiovascular. Its pipeline of products includes Rexista Oxycodone, Regabatin XR, Generic Focalin XR, Generic Effexor XR, Generic Protonix, Generic Glucophage XR, Generic Seroquel XR, Generic Lamictal XR, Generic Keppra XR, Generic Pristiq and Generic Ranexa. Its generic product candidates also include Trazodone hydrochloride extended-release tablets and Carvedilol phosphate extended-release capsules.
Receive News & Ratings for Intellipharmaceutics International Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intellipharmaceutics International Inc. and related companies with MarketBeat.com's FREE daily email newsletter.